Staking out CNS

Third Rock Ventures expects its $35 million investment in a single company - Sage Therapeutics Inc. - will give the firm a play on a spectrum of central nervous system disorders.

The firm was the sole investor in Sage's series A round. Third Rock's Kevin Starr, who also is the company's interim CEO, expects the financing should allow Sage to advance four to five candidates into the clinic over the next three or four years...